Search

Meet Stefan Fröhling, our November volunteer of the month

Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.

Read more

Meet Stefan Fröhling, our November volunteer of the month

Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.

Read more

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes.

Read more

European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

Read more

Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

PRESS RELEASE
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

The Hague, Wednesday 18, November, 2020

The field of cell and gene therapy is one of the most…

Read more

EU health policy: limited scope, high ambition

Over the past decades, the European Union (EU) has become more involved in public health policy. A recent study showed that a majority of policymakers even identifies EU health policy as a priority for 2020-20241.

Read more

EHA-LSHBT Virtual Hematology Updates

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.

Read more

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more